Accelerate Diagnostics traded at $0.86 this Tuesday April 9th, decreasing $0.06 or 6.19 percent since the previous trading session. Looking back, over the last four weeks, Accelerate Diagnostics lost 24.56 percent. Over the last 12 months, its price fell by 87.89 percent. Looking ahead, we forecast Accelerate Diagnostics to be priced at 0.84 by the end of this quarter and at 0.79 in one year, according to Trading Economics global macro models projections and analysts expectations.
Accelerate Diagnostics, Inc. is an vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.